

The Path to Approved Treatments for **NF2-SWN**

From SYNODOS to INTUITT and Beyond

Tune in for a not-to-be-missed webinar from the Children's Tumor Foundation for an important announcement of the results of the INTUITT-NF2 platform clinical trial, and more.

Extraordinary things are underway in the search for effective treatments for NF2-related schwannomatosis and all forms of schwannomatosis. Learn about:

- INTUITT's innovative platform basket trial design, and the encouraging first results
- CTF's game-changing investment in the global SYNODOS "dream team" preclinical consortium
- SYNODOS' groundbreaking screening process that identified promising treatments, including brigatinib

Innovative researchers, courageous patients, and bold investors have galvanized NF2-SWN research to a very pivotal moment.

Be among the first to learn what's happening now, and how you can be a part of what's next on the NF2-SWN horizon.

All are invited to attend. Registration is free. Captioning will be available.

September 27, 2023 7:00 PM ET

Captioning will be available.

Speakers:



Annette Bakker, PhD
President, Children's Tumor Foundation

Scott Plotkin, MD, PhD
Massachusetts General Hospital



Brigid Garelik, MD, MPH
Chief Medical Officer, Children's Tumor Foundation



Register today: ctf.org/nf2swn